Trials / Active Not Recruiting
Active Not RecruitingNCT02502786
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 13 Months – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | humanized anti-GD2 antibody | |
| DRUG | GM-CSF |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2015-07-20
- Last updated
- 2025-10-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02502786. Inclusion in this directory is not an endorsement.